Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Comorbidities

Should cancer screening be routine in rheumatoid arthritis?

Nature Reviews Rheumatology volume 5, pages 474–475 (2009)Cite this article

The degree to which the elevated risk of malignant lymphomas in patients with rheumatoid arthritis (RA) is related to disease activity or to therapy is uncertain. Evidence is mounting in support of a strategy of more-intensive cancer screening in these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Askling, J., Klareskog, L., Blomqvist, P., Fored, M. & Feltelius, N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case–control study. Ann. Rheum. Dis. 65, 1184–1187 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Stern, R. S. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch. Dermatol. 142, 1132–1135 (2006).

    PubMed  Google Scholar 

  3. Askling, J. et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann. Rheum. Dis. 68, 648–653 (2009).

    Article  CAS  PubMed  Google Scholar 

  4. Askling, J. et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis. 66, 1339–1344 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systematic review and meta-analysis of rare harmful effects in randomized clinical trials. JAMA 295, 2275–2285 (2006).

    Article  CAS  Google Scholar 

  6. Bongartz, T. et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data meta-analysis of randomized controlled trials. Ann. Rheum. Dis. 68, 1177–1183 (2009).

    Article  CAS  PubMed  Google Scholar 

  7. Nannini, C. et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum. 61, 801–812 (2009).

    Article  CAS  PubMed  Google Scholar 

  8. Wolfe, F. & Michaud, K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50, 1740–1751 (2004).

    Article  CAS  PubMed  Google Scholar 

  9. Baecklund, E., Ekbom, A., Sparén, P., Feltelius, N. & Klareskog, L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case–control study. BMJ 317, 180–181 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hellgren, K. et al. Rheumatoid arthritis, treatment with corticosteroids, and risk of malignant lymphomas—results from a case–control study. Ann. Rheum. Dis. doi:10.1136/ard.2008.096925.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Mayo Clinic School of Medicine, Rochester, MN, USA

    Eric L. Matteson

Authors
  1. Eric L. Matteson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric L. Matteson.

Ethics declarations

Competing interests

The author declares that he has acted as a consultant for and received research support from the following companies: Abbot, Amgen, Centocor and Wyeth. In addition, the author has received research support from the following companies: Genentech and Bristol Myers Squibb.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matteson, E. Should cancer screening be routine in rheumatoid arthritis?. Nat Rev Rheumatol 5, 474–475 (2009). https://doi.org/10.1038/nrrheum.2009.173

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.173

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing